New Zealand is considering a proposal to expand funded influenza vaccinations to younger children and secure the long-term supply of several vaccines in the national immunisation programme. According to a government announcement on 21 May 2026, the initiative would widen eligibility for funded flu vaccines to children aged between six months and five years, while also updating supply agreements and vaccine brands to improve protection for certain population groups.
The proposal has been developed by Pharmac, New Zealand’s pharmaceutical management agency. Associate Health Minister Mr David Seymour said vaccines play an important role in preventing illness and delivering long-term public health value.
Expanding Flu Vaccine Access for Young Children
If approved, the proposal would make funded influenza vaccines available to all children aged six to 59 months. Officials estimate that around 260,000 additional children would become eligible for a funded flu vaccine starting in the 2027 influenza season.
In total, more than 1.5 million people are expected to receive vaccines covered by the proposal in the first year of funding. The policy aims to reduce the burden of seasonal influenza and improve protection for vulnerable groups through earlier immunisation.
Updating Vaccine Supply and Protection Levels
The proposal also includes securing ongoing supply agreements for 17 vaccines and one diagnostic test used within the National Immunisation Schedule. Pharmac is additionally considering changes to several vaccine brands, including meningococcal ACWY, pneumococcal and influenza vaccines.